Our study suggests that pharmacological approaches to specifically target and enhance chaperone-dependent aggregate processing may restore proteostasis in individuals with ALS, sIBM, and other TDP-43 proteinopathies. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.